alrizomadlin,pembrolizumab
ascentage pharmaceuticals,merck
['ascent', 'alrizomadlin', 'melanoma', 'pembro', 'ascentage']
dcbn news: live from asco 2023 | for the third consecutive year, ascentage pharma releases promising results of alrizomadlin plus pembrolizumab in patients with cutaneous melanoma that failed ... #biotech #news 
Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008.